RxDoctor Payments Data

Warren Levy, MD

Cardiovascular Disease · Arlington, VANPI 1174520795

Payments from drug & device makers

$852in general payments, 2019–2025

Across 31 payments — averaging $27.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$271
  • Pfizer$203
  • Amgen$166
  • Johnson & Johnson$86
  • Scpharmaceuticals Inc.$70
  • Kiniksa Pharmaceuticals, Ltd.$23
  • plus $34 from 2 others

What the payments were for

  • Food & beverage$82897%
  • Education$243%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$852 in reported general payments places this provider in the 35th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$109,397
Medicare patients
676
Services billed
1,575

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban135$195,332
EntrestoSacubitril/Valsartan19$28,313
JardianceEmpagliflozin16$26,464
XareltoRivaroxaban12$20,226
Repatha SureclickEvolocumab16$19,260
Metoprolol Succinate137$2,209
Atorvastatin Calcium156$1,569
Losartan Potassium78$1,171
Diltiazem 24hr Er (Cd)Diltiazem Hcl28$855
Rosuvastatin Calcium46$801
ClopidogrelClopidogrel Bisulfate40$724
Amlodipine Besylate63$674
Valsartan13$357
Hydrochlorothiazide51$351
Isosorbide Mononitrate ErIsosorbide Mononitrate18$343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$203$195,332135 claims
NovartisEntresto$271$28,31319 claims
Johnson & JohnsonXarelto$86$20,22612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Arlington

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →